Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.20 USD
Change Today -0.20 / -5.88%
Volume 93.6K
CBLI On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 5:20 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

cleveland biolabs inc (CBLI) Snapshot

Open
$3.40
Previous Close
$3.40
Day High
$3.60
Day Low
$3.20
52 Week High
09/3/14 - $13.80
52 Week Low
04/22/15 - $3.05
Market Cap
11.0M
Average Volume 10 Days
79.9K
EPS TTM
$-2.93
Shares Outstanding
3.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CLEVELAND BIOLABS INC (CBLI)

Related News

No related news articles were found.

cleveland biolabs inc (CBLI) Related Businessweek News

View More BusinessWeek News

cleveland biolabs inc (CBLI) Details

Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate is Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is developing as a radiation countermeasure for prevention of death from acute radiation syndrome, and as an oncology drug. The company is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma and activates NF-kB pro-survival and immunoregulatory signaling pathways; CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer; and Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin. It has license agreements and collaborations with the Cleveland Clinic Foundation and Roswell Park Cancer Institute. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.

13 Employees
Last Reported Date: 04/10/15
Founded in 2003

cleveland biolabs inc (CBLI) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $302.3K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $119.3K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $283.2K
Compensation as of Fiscal Year 2014.

cleveland biolabs inc (CBLI) Key Developments

Cleveland BioLabs, Inc. - Shareholder/Analyst Call

Annual Meeting

Cleveland BioLabs, Inc. Announces Completion of Dosing in Phase 1 Study of CBLB612 in Russian Federation

Cleveland BioLabs, Inc. announced that a maximally tolerated dose has been reached and that dosing has been completed in a Phase 1 healthy subject study of CBLB612, an investigational drug in development for mobilization of hematopoietic stem cells (HSCs) and for the prevention of chemotherapy-induced myelosuppression. The objectives of the study include establishing a maximally tolerated dose, evaluating the safety profile and pharmacokinetics of CBLB612, and characterizing the type, quantity and timing of HSC mobilization. Analysis of data from the 56 healthy volunteers enrolled in the study is ongoing and data are expected to be reported in the second quarter of 2015. This study is partially funded through a contract from the Ministry of Industry and Trade of the Russian Federation.

Cleveland BioLabs, Inc. Receives Non-Compliance Notice From NASDAQ

On March 10, 2015, Cleveland BioLabs, Inc. received a deficiency letter from The NASDAQ Stock Market LLC indicating that, as of December 31, 2014 the company’s reported stockholders’ equity of $1,786,102 did not meet the $2,500,000 minimum required to maintain continued listing, as set forth in NASDAQ Listing Rule 5550(b)(1), and that as of March 9, 2015 the company does not meet the alternatives of market value of listed securities or net income from continuing operations. The notification has no immediate effect on the listing of the company’s common stock on the Nasdaq Capital Market. Under NASDAQ rules, the company has 45 calendar days to submit a plan to regain compliance. If the company’s plan is accepted, NASDAQ can grant an extension of up to 180 calendar days, or until September 7, 2015, to evidence compliance. If the company fails to regain compliance, the company’s stock will be subject to delisting by NASDAQ. The company is considering actions that it may take in response to this notification in order to regain compliance with the continued listing requirements.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBLI:US $3.20 USD -0.20

CBLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBLI.
View Industry Companies
 

Industry Analysis

CBLI

Industry Average

Valuation CBLI Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLEVELAND BIOLABS INC, please visit www.cbiolabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.